Pharmacologic Interventions in the Treatment of Temporomandibular Disorders, Atypical Facial Pain, and Burning Mouth Syndrome. A Qualitative Systematic Review

Aims: To carry out a systematic review of the literature in order to assess the pain-relieving effect and safety of pharmacologic inter-ventions in the treatment of chronic temporomandibular disorders (TMD), including rheumatoid arthritis (RA), as well as atypical facial pain (AFP), and burning mouth syndrome (BMS). Methods: Study selection was based on randomized clinical trials (RCTs). Inclusion criteria included studies on adult patients (≥ 18 years) with TMD, RA of the temporomandibular joint (TMJ), AFP, or BMS and a pain duration of ＞ 3 months. Data sources included Medline, Cochrane Library, Embase, and PsychLitt. Results: Eleven studies with a total of 368 patients met the inclusion crite-ria. Four trials were on TMD patients, 2 on AFP, 1 on BMS, 1 on RA of the TMJ, and 3 on mixed groups of patients with TMD and AFP. Of the latter, amitriptyline was effective in 1 study and ben-zodiazepine in 2 studies; the effect in 1 of the benzodiazepine stud-ies was improved when ibuprofen was also given. One study showed that intra-articular injection with glucocorticoid relieved the pain of RA of the TMJ. In 1 study, a combination of paraceta-mol, codeine, and doxylamine was effective in reducing TMD pain. No effective pharmacologic treatment was found for BMS. Only minor adverse effects were reported in the studies. Conclusion: The common use of analgesics in TMD, AFP, and BMS is not supported by scientific evidence. More large RCTs are needed to determine which pharmacologic interventions are effective in TMD, AFP, and BMS.

orofacial pain; pharmacologic treatment; randomized clinical trials; systematic review; temporomandibular disorders

1. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 1993;124(10):115–121.

2. Okeson JP (ed). Orofacial Pain: Guidelines for Assess-ment, Diagnosing and Management. Chicago: Quintessence, 1996.

3. McNeill C, Dubner R. What is pain and how do we classify orofacial pain? In: Lund JP, Lavigne GL, Dubner R, Sessle BJ (eds). Orofacial Pain. From Basic Science to Clinical Management. Chicago: Quintessence, 2001: 183–192.

4. Zarzewska JM, Hamlyn PJ. Facial pain. In: Crombie IK, Croft PR, Linton SL, LeResche L, Von Korff M (eds). Epidemiology of Pain. Seattle: IASP Press, 1999:171–202.

5. Drangsholt M, LeResche L. Epidemiology of temporo-mandibular pain. In: Crombie IK, Croft PR, Linton SL, LeResche L, Von Korff M (eds). Epidemiology of Pain. Seattle: IASP Press, 1999:203–233.

6. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6:301–355.

7. Woda A. Mechanisms of neuropathic pain. In: Lund JP, Lavigne GL, Dubner R, Sessle BJ (eds). Orofacial Pain. From Basic Science to Clinical Management. Chicago: Quintessence, 2000:67–78.

8. Ship JA, Grushka M, Lipton JA, Mott AE, Sessle BJ, Dionne RA. Burning mouth syndrome: An update. J Am Dent Assoc 1995;126:842–853.

9. Von Korff M, Dworkin SF, LeResche L, Kruger A. An epidemiologic comparison of pain complaints. Pain 1988;32: 173–183.

10. Smith DP, Pilling LF, Pearson JS, Rushton JG, Goldstein NP, Gibilisco JA. A psychiatric study of atypical facial pain. Can Med Assoc J 1969;100:286–291.

11. List T, Dworkin SF. Comparing TMD diagnoses and clinical findings at Swedish and US TMD centers using research diagnostic criteria for temporomandibular disor-ders. J Orofac Pain 1996;10:240–253.

12. Mohl ND. The anecdotal tradition and the need for evidence-based care for temporomandibular disorders. J Orofac Pain 1999;13:227–231.

13. Antczak-Bouckoms AA. Epidemiology of research for tem-poromandibular disorders. J Orofac Pain 1995;9:226–234.

14. De Kanter RJ, Truin GJ, Burgersdijk RC, et al. Prevalence in the Dutch adult population and a meta-analysis of signs and symptoms of temporomandibular disorder. J Dent Res 1993;72:1509–1518.

15. Ernst E, White AR. Acupuncture as a treatment for tem-poromandibular joint dysfunction: A systematic review of randomized trials. Arch Otolaryngol Head Neck Surg 1999;125:269–272.

16. Crider AB, Glaros AG. A meta-analysis of EMG biofeed-back treatment of temporomandibular disorders. J Orofac Pain 1999;13(1):29–37.

17. Forssell H, Kalso E, Koskela P, Vehmanen R, Puukka P, Alanen P. Occlusal treatments in temporomandibular disorders: A qualitative systematic review of randomized controlled trials. Pain 1999;83:549–560.

18. Zakrewska JM, Glenny AM, Forssell H. Intervention for treatment of burning mouth syndrome. In: Issue 1 ed. Cochrane Library, Oxford: Update Software, 2002.

19. Denucci DJ, Dionne RA, Dubner R. Identifying a neurobiologic basis for drug therapy in TMDs. J Am Dent Assoc 1996;127:581–593.

20. Von Korff M, Galer BS, Stang P. Chronic use of symp-tomatic headache medications. Pain 1995;62:179–186.

21. Truelove EL. The chemotherapeutic management of chronic and persistent orofacial pain. Dent Clin North Am 1994;38:669–688.

22. Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: A review. J Am Dent Assoc 2000;131:184–195.

23. Silverstein FE, Faich G, Goldstein JL, et al. Gastro-intestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–1255.

24. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–1528, 2 p following 1528.

25. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992;268:240–248.

26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1–12.

27. Gerschman JA, Reade PD, Burrows GD. Evaluation of a proprietary analgesic/antihistamine in the management of pain associated with temporomandibular joint pain dysfunction syndrome. Aust Dent J 1984;29:300–304.

28. Singer E, Dionne R. A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. J Orofac Pain 1997;11:139–146.

29. Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain 1987;31:199–209.

30. Feinmann C. Psychogenic facial pain: Presentation and treatment. J Psychosom Res 1983;27:403–410.

31. Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: A placebo-controlled, double-blind study. J Orofac Pain 1999;13:83–88.

32. Harkins S, Linford J, Cohen J, Kramer T, Cueva L. Administration of clonazepam in the treatment of TMD and associated myofascial pain: A double-blind pilot study. J Craniomandib Disord 1991;5:179–186.

33. DeNucci DJ, Sobiski C, Dionne RA. Triazolam improves sleep but fails to alter pain in TMD patients. J Orofac Pain 1998;12:116–123.

34. Kopp S, Akerman S, Nilner M. Short-term effects of intraarticular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporomandibu-lar joint. J Craniomandib Disord 1991;5:231–238.

35. Schwartz G, Galonski M, Gordon A, Shandling M, Mock D, Tenenbaum HC. Effects of salmon calcitonin on patients with atypical (idiopathic) facial pain: A randomized controlled trial. J Orofac Pain 1996;10:306–315.

36. Al Balawi S, Tariq M, Feinmann C. A double-blind, placebo-controlled, crossover study to evaluate the efficacy of subcutaneous sumatriptan in the treatment of atypical facial pain. Int J Neurosci 1996;86(3–4):301–309.

37. Marbach JJ, Wallenstein SL. Analgesic, mood, and hemo-dynamic effects of intranasal cocaine and lidocaine in chronic facial pain of deafferentation and myofascial origin. J Pain Symptom Manage 1988;3:73–79.

38. McQuay HJ, Moore RA. Methods of therapeutical trials. In: Wall PD, Melzack R (eds). Textbook of Pain, ed 4. Edinburgh: Churchill Livingstone, 1999:1125–1138.

39. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Failure to conceal treatment allocation schedules in trials influences estimates of treatment effects. Control Clin Trials 1994; 15:63–64.

40. Scottish Intercollegiate Guidelines Network (SIGN). Sign 50: A guideline developer’s handbook. Available at: http:www.sign.ac.uk/guidelines/fulltext/50/index.html.

41. Max MB, Laska EM. The design of analgesic trials. In: Max MB, Portenoy RK, Laska EM (eds). Advances in Pain Research and Therapy. New York: Raven, 1991: 55–95.

42. James KE, Forrest WH Jr, Rose RL. Crossover and non-crossover designs in four-point parallel line analgesic assays. Clin Pharmacol Ther 1985;37:242–252.

43. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything—Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78:209–216.

44. McQuay HJ, Moore RA. An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press, 1998.

45. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301:1410–1412.

46. Ekberg EC, Kopp S, Akerman S. Diclofenac sodium as an alternative treatment of temporomandibular joint pain. Acta Odontol Scand 1996;54:154–159.

47. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217–227.

48. Sindrup SH, Jensen TS. Efficacy of pharmacologic treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389–400.

49. Monks R, Merskey H. Psychotropic drugs. In: Wall PD, Melzack R (eds). Textbook of Pain, ed 4. Edinburgh: Churchill Livingstone, 1999:1155–1186.

50. King SA, Strain JJ. Benzodiazepines and chronic pain. Pain 1990;41:3–4.

51. Rozental TD, Sculco TP. Intra-articular corticosteroids: An updated overview. Am J Orthop 2000;29:18–23.

52. Acton CH. Steroid-induced anterior open bite. Case report. Aust Dent J 1986;31:455–458.

53. Aggarwal S, Kumar A. A cortisone-wrecked and bony ankylosed temporomandibular joint. Plast Reconstr Surg 1989;83:1084–1085.

54. Wenneberg B, Kopp S, Grondahl HG. Long-term effect of intraarticular injections of a glucocorticosteroid into the TMJ: A clinical and radiographic 8-year follow-up. J Craniomandib Disord 1991;5:11–18.

55. Bogetto F, Revello RB, Ferro G, Maina G, Ravizza L. Psychopharmacologic treatment of burning mouth syndrome (BMS). Minerva Psichiatr 1999;40:1–10.

56. Feinmann C, Harris M. Psychogenic facial pain. Part 2: Management and prognosis. Br Dent J 1984;156:205–208.

57. Feinmann C, Harris M, Cawley R. Psychogenic facial pain: Presentation and treatment. Br Med J (Clin Res Ed) 1984;288(6415):436–438.

58. Franks AS. Mandibular spasm: A double-blind study of a muscle relaxant drug. Br J Clin Pract 1965;19:298–384.

59. Gallardo F, Molgo J, Miyazaki C, Rossi E. Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. J Oral Surg 1975;33:655–658.

60. Greene CS, Laskin DM. Meprobamate therapy for the myofascial pain-dysfunction (MPD) syndrome: A double-blind evaluation. J Am Dent Assoc 1971;82:587–590.

61. Harrison SD, Balawi SA, Feinmann C, Harris M. Atypical facial pain: A double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan. Eur Neuropsy-chopharmacol 1997;7:83–88.

62. Lascelles RG. Atypical facial pain and depression. Br J Psychiatry 1966;112:651–659.

63. Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharma-cology 1989;99:1–7.

64. Rossi E, Gallardo F, Weil MW. Prazepam as the initial treatment of myofacial pain-dysfunction syndrome. IRCS Med Sci 1983;7:637–638.

65. Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:683–686.

66. Schwartz L, Kutscher AH, Yavelow I, Cobin HP, Brod MS. Carisoprodol in the management of temporo-mandibular joint pain and dysfunction: A preliminary investigation. Ann NY Acad Sci 1960;86:245–249.

67. Shin SM, Choi JK. Effect of indomethacin phonophoresis on the relief of temporomandibular joint pain. Cranio 1997;15:345–348.

68. Seltzer S, Dewart D, Pollack RL, Jackson E. The effects of dietary tryptophan on chronic maxillofacial pain and experimental pain tolerance. J Psychiatr Res 1982;17: 181–186.

69. Stockstill JW, McCall WD, Jr, Gross AJ, Piniewski B. The effect of L-tryptophan supplementation and dietary instruction on chronic myofascial pain. J Am Dent Assoc 1989;118:457–460.